Tivic Health (TIVC) announced it has completed all study visits in the Optimization Study for its non-invasive cervical vagus nerve stimulation device. The study, conducted by The Feinstein Institute of Bioelectronic Medicine, aimed to identify device parameters that optimally influence autonomic nervous system function. Tivic expects to release study results later this year and apply the findings to an upcoming Phase I clinical trial.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIVC: